<DOC>
	<DOCNO>NCT01928524</DOCNO>
	<brief_summary>The purpose study determine maximal tolerable dose ( MTD ) combination docetaxel , oxaliplatin S1 ( DOS ) patient gastric cancer .</brief_summary>
	<brief_title>Chemotherapy Patients With Cancer Stomach</brief_title>
	<detailed_description>The primary aim dose-finding study determine maximum tolerated dos docetaxel , oxaliplatin S1 give every second ( DOS2w ) third ( DOS3w ) week first-line treatment patient advance gastro-esophageal cancer . Secondary end point evaluate toxicity accord NCI-CTCAE v. 4 , response rate , progression-free survival overall survival Primary Outcome Measure : To determine maximum tolerate dose ( MTD ) combination regime ( DOS2w ) ( DOS3w ) . The investigator plan examine 4 dose level ( DOS2w ) 3 dose level ( DOS3w ) . Methods : This dose-finding study plan include total 24 patient advanced gastro-esophageal cancer , adenocarcinoma . 12 patient include ( DOS2w ) four progressively high dose level . Chemotherapy repeat day 1 every second week maximum nine course . 12 patient include ( DOS3w ) three progressively high dose level . Chemotherapy repeat day 1 every third week maximum six course . In ( DOS2w ) ( DOS3w ) dose-limiting toxicity ( DLT ) evaluate first course . In case DLT among one three patient first course treatment additional three patient add respective dose level . Dose escalation continue 0/3 1/6 patient experience DLT . Patients evaluate ct-scan baseline every three four cycle exclude progression evaluate response . Response assess investigator accord RECIST version 1.1 .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Histological proven adenocarcinoma esophagus ventricle ( ECV ) , treat curatively . 2 . Age ≥ 18 year . 3. WHO performance status 01 . 4 . Neutrophils ≥ 1,5 x 109/L platelet ≥ 100 x 109/L . 5 . Bilirubin ≤ 1,5 x UNL ( Upper Normal Limit ) ASAT and/or ALAT ≤ 3 x UNL . 6 . Creatinineclearance ≥ 60 ml/min . 7 . Planned first day treatment within 8 day inclusion study . 8 . Signed consent form . 1 . No previous treatment chemotherapy , except ( neo ) adjuvant chemotherapy adenocarcinoma treatment complete least 6 month entrance study . 2 . No sensory neuropathy . 3 . No previously treatment docetaxel , oxaliplatin S1 . 4 . No clinical suspicion brain metastasis . 5 . No cytotoxic treatment experimental treatment within 2 week inclusion study . 6 . Other serious disease ( i.e . heart disease , AMI within 1 year ongoing infection ) . 7 . No pregnant woman woman lactate . Patients use contraception . 8 . No known DPDdeficiency know allergy taxanes platinum . 9 . No sign physical mental illness would prevent absorption oral treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Gastric cancer</keyword>
	<keyword>Cancer esophagus</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>S1</keyword>
</DOC>